Home How It Works Goals Protocols Lab Tests Peptides Blog About Log In Get Started

★ The Only FDA-Approved GH Secretagogue

Tesamorelin (Egrifta) — FDA-Approved GHRH Analog

Tesamorelin, marketed as Egrifta by Theratechnologies, received FDA approval in November 2010 (NDA 022505) for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy — making it the only GH secretagogue compound with FDA approval for any adult body composition indication. Its Phase 3 clinical program represents the strongest human evidence available in the GHS class. Evidence level: Level I (Phase 3 RCT data, FDA-approved indication).

Start a Consultation Back to GH Secretagogues

FDA approval — read this first

Tesamorelin is the only FDA-approved GH secretagogue. Understanding this distinction matters.

★ FDA Approval: Egrifta (Theratechnologies) — November 2010

Tesamorelin received FDA approval on November 10, 2010 under NDA 022505, marketed as Egrifta by Theratechnologies Inc. The approved indication is: treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. This is the only FDA approval for any GH secretagogue compound for an adult body composition indication. No other compound in this class — not CJC-1295, ipamorelin, sermorelin, or MK-677 — has received FDA approval for any adult indication.

The FDA approval is indication-specific: it applies exclusively to HIV-associated lipodystrophy. Use of tesamorelin for body composition optimization in non-HIV populations, for aging-related GH support, or for any indication other than HIV lipodystrophy constitutes off-label use. Off-label prescribing is legal and common in clinical medicine — but it does not carry the same evidentiary weight as the approved indication, and it is not supported by the Phase 3 clinical data that earned the approval. Clinicians must document clinical rationale when prescribing off-label.

What tesamorelin is

A stabilized GHRH analog engineered for metabolic stability and pituitary specificity.

Tesamorelin's molecular design distinguishes it from earlier GHRH analogs like sermorelin and from the CJC-1295 family. Understanding its structure explains both its clinical performance and its pharmacological profile.

Molecular Structure — Stabilized GHRH Analog

Tesamorelin is a synthetic analog of the full 44-amino acid endogenous GHRH, with a critical chemical modification: a trans-3-hexenoic acid group attached to the N-terminal amino acid (tyrosine). This modification dramatically improves metabolic stability — protecting the molecule from dipeptidyl peptidase IV (DPP-IV) cleavage that would otherwise rapidly degrade unmodified GHRH in circulation. The modification extends effective half-life and GHRH receptor engagement time without the albumin-binding mechanism used in CJC-1295 with DAC. Tesamorelin retains the full 44-amino acid GHRH sequence, distinguishing it structurally from the truncated 1-29 fragment used by sermorelin.

GHRH Receptor Agonism — Mechanism

Tesamorelin binds to and activates GHRH receptors on anterior pituitary somatotroph cells. Receptor activation triggers the adenylyl cyclase/cAMP/PKA signaling cascade, stimulating GH synthesis and secretion. The released GH travels to the liver and peripheral tissues, stimulating IGF-1 production and activating the full GH/IGF-1 signaling axis. Tesamorelin's mechanism is identical in receptor target and signaling pathway to endogenous GHRH and to other GHRH analogs — its distinction is in metabolic stability and the completeness of the amino acid sequence.

HIV-Associated Lipodystrophy — The Approved Context

HIV-associated lipodystrophy is a body composition abnormality affecting HIV-positive patients — characterized by excess visceral and dorsal fat accumulation, peripheral fat loss (lipoatrophy), and metabolic disturbances including dyslipidemia and insulin resistance. It is attributed to both HIV infection itself and to long-term antiretroviral therapy (ART), particularly older nucleoside reverse transcriptase inhibitors and protease inhibitors. Tesamorelin's Phase 3 trials were conducted specifically in this population, where the GH/IGF-1 axis dysregulation that characterizes lipodystrophy provides a specific therapeutic target for GHRH analog intervention.

Pulsatile GH Preservation

As a GHRH-class compound, tesamorelin stimulates the pituitary's endogenous GH release while preserving pulsatile secretion and physiologic feedback regulation. The Phase 3 trial data confirm that GH levels rose in a pattern consistent with endogenous GH dynamics — not a continuous, non-pulsatile elevation. Somatostatin-mediated negative feedback remains functional throughout treatment. This physiologic preservation is the theoretical basis for the favorable glucose profile observed in the tesamorelin clinical program — unlike exogenous GH, which continuously elevates circulating GH without physiologic feedback damping.

Pharmacokinetics

Tesamorelin is administered subcutaneously once daily. The FDA-approved dose is 2 mg. Peak plasma concentration is achieved within approximately 15 minutes of subcutaneous injection. The half-life is approximately 26–38 minutes — longer than sermorelin due to the N-terminal modification, but shorter than CJC-1295 without DAC. It is metabolized by proteolytic enzymes and cleared rapidly from circulation. The short plasma half-life of the parent molecule belies its sustained pharmacological effect: pituitary stimulation produces GH pulses that persist beyond the period of measurable plasma tesamorelin.

Egrifta SV — 2019 Formulation Update

Theratechnologies introduced Egrifta SV (a single-vial, liquid formulation) in 2019 as an updated delivery system compared to the original lyophilized two-vial kit. Egrifta SV offers a more convenient preparation method with the same active compound and dosing. Both formulations are considered equivalent in pharmacological activity. The availability of an improved formulation from the FDA-approved manufacturer reflects ongoing commercial investment in the approved indication — a distinguishing feature from unapproved GHS compounds.

Clinical evidence

Phase 3 RCT data and 2026 meta-analysis — the strongest evidence in the GHS class.

Tesamorelin's evidence base is categorically different from other GHS compounds: it is the product of an FDA-regulated clinical development program with double-blind, randomized, placebo-controlled Phase 3 trials. All PMIDs below are verified against PubMed as of May 2026.

Phase 3 Pivotal Pooled Analysis — Regulatory Approval Basis

PMID: 20554713 · Falutz et al., J Clin Endocrinol Metab 2010 · Evidence: Level I (Phase 3 RCT)

The FDA approval was based on a pooled analysis of two double-blind, randomized, placebo-controlled Phase 3 trials (n=806 HIV-positive patients with lipodystrophy). Tesamorelin 2 mg/day subcutaneous significantly reduced visceral adipose tissue (VAT) by a mean of −24 cm² versus a gain of +2 cm² with placebo (treatment effect −15.4%, p<0.001) at 26 weeks. The reduction was sustained at 52 weeks. Secondary endpoints also improved significantly: triglycerides, cholesterol-to-HDL ratio, and patient-reported body image scores. Glucose parameters were not clinically meaningfully affected — a notable finding in a population with pre-existing metabolic disturbances. This represents the highest quality evidence available for any GHS compound.

2026 Meta-Analysis — Confirming and Expanding the Evidence

DOI: 10.1016/j.orcp.2026.01.002 · Badran et al. 2026 · Evidence: Level I (meta-analysis of RCTs)

This 2026 meta-analysis of 5 RCTs confirmed and expanded the Phase 3 findings. Pooled results across the RCTs demonstrated tesamorelin significantly reduced: VAT (mean difference −27.71 cm², p<0.001); trunk fat; hepatic fat fraction; and waist circumference. Simultaneously, tesamorelin increased lean body mass (mean difference +1.42 kg, p<0.001). Treatment was well tolerated — the primary adverse effects were musculoskeletal complaints (arthralgia, myalgia) and injection site reactions. This 2026 meta-analysis represents the most current and comprehensive evidence synthesis for tesamorelin's body composition effects.

Hepatic Fat — Emerging Evidence

Evidence: Level II–III (secondary endpoints and exploratory analyses)

Secondary and exploratory analyses from the tesamorelin clinical program have consistently shown reduction in hepatic fat fraction — a metabolically significant endpoint, as non-alcoholic fatty liver disease (NAFLD/MASH) is highly prevalent in the HIV lipodystrophy population. Tesamorelin's effects on hepatic fat are among the most clinically interesting aspects of its off-label interest, as hepatic steatosis is a growing concern in metabolic syndrome populations beyond HIV. These hepatic effects were confirmed in the 2026 meta-analysis (Badran et al.) but are not part of the FDA-approved label claims.

GHS in Adult Males — Systematic Review Context

DOI: 10.21037/tau.2019.11.30 · Sinha et al. 2020 · Evidence: Level III (systematic review)

The Sinha et al. 2020 systematic review of GH secretagogues in adults identified tesamorelin as the compound with the strongest clinical evidence in the GHS class, specifically noting its Level I Phase 3 data as distinguishing it from sermorelin, ipamorelin, and MK-677. The review confirmed that tesamorelin's body composition effects in HIV lipodystrophy are the most evidence-supported GHS outcomes in any compound, while noting that extrapolation to non-HIV adults requires clinical caution.

Dosing context

FDA-approved dosing and off-label clinical use.

FDA-Approved Dose — Egrifta

The FDA-approved dose of tesamorelin (Egrifta) is 2 mg subcutaneous once daily for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. This is the dose studied in the Phase 3 trials and supported by the approval label. Administration is by subcutaneous injection in the abdomen. Egrifta SV (the single-vial liquid formulation) is typically reconstituted per manufacturer instructions before injection.

Off-Label Use — Clinical Context

Off-label use of tesamorelin in non-HIV populations — for body composition optimization in healthy aging adults, metabolic syndrome, or longevity protocols — occurs in clinical practice. There is no FDA-approved indication for these uses. Off-label dosing often mirrors the approved 2 mg/day protocol, though some clinicians titrate based on individual IGF-1 response. Clinicians must document clinical rationale for off-label prescribing. The evidence supporting off-label use is primarily extrapolated from the HIV lipodystrophy trials and does not have the same RCT validation for non-HIV populations.

Compounded Tesamorelin — Regulatory Nuance

Because Egrifta is an FDA-approved branded product, 503A compounding of tesamorelin for non-HIV patients operates in a gray zone requiring clear prescriber documentation of clinical rationale — similar to off-label prescribing of any approved branded drug. Compounding an essentially identical copy of an FDA-approved product without patient-specific clinical need is not consistent with FDA 503A guidance. A licensed prescriber must document the specific individualized patient need that the commercially available product does not address. This is a legal and compliance matter requiring attorney and pharmacy guidance.

IGF-1 Monitoring

As with all GHS protocols, baseline IGF-1 measurement before initiating tesamorelin is standard practice. The Phase 3 trials monitored IGF-1 as a pharmacodynamic endpoint. Follow-up monitoring at 4–8 weeks and periodically thereafter guides dose appropriateness. IGF-1 should remain within a physiologically healthy range for the patient's age. Clinicians should also monitor fasting glucose and HbA1c, particularly in off-label use populations where metabolic context differs from the HIV lipodystrophy trial population.

Safety considerations

FDA-approved label safety data — and considerations for off-label use.

Tesamorelin has the most extensive human safety dataset of any GHS compound — the product of an FDA clinical development program in over 800 patients. The following summarizes both the FDA-approved label safety profile and additional considerations for off-label clinical use.

Most Common Adverse Effects — Phase 3 Data

In the Phase 3 trials, the most common adverse effects of tesamorelin (occurring more frequently than placebo) were: injection site reactions (erythema, pruritus, pain — approximately 25–35% incidence, primarily mild); arthralgia (joint pain); myalgia (muscle aches); peripheral edema; and hypoesthesia (reduced sensation) or paresthesia (tingling). These effects were generally mild to moderate and manageable. The 2026 meta-analysis confirmed musculoskeletal complaints and injection site reactions as the primary tolerability concerns.

Glucose Parameters — Favorable Signal

A notable finding from the tesamorelin clinical program is that glucose parameters were not clinically meaningfully affected despite the GH elevation — a more favorable glucose profile than might be expected from a GH-elevating compound. The Phase 3 trials monitored fasting glucose and HbA1c; neither was significantly changed from baseline with tesamorelin in the HIV lipodystrophy population. This may reflect tesamorelin's pulsatile GH stimulation mechanism and preserved physiologic feedback, but glucose monitoring remains appropriate in clinical practice for any GHS protocol.

Formal Contraindications — FDA Label

Tesamorelin is formally contraindicated (per the FDA-approved label) in patients with: disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor, pituitary surgery, head irradiation, or traumatic brain injury; active malignancy; pregnancy; and known hypersensitivity to tesamorelin or excipients. These are hard contraindications applicable to all tesamorelin use — approved or off-label.

Fluid Retention and Musculoskeletal Effects

Peripheral edema and arthralgia/myalgia are the most commonly reported tolerability concerns and are class-level GH effects. Water retention typically diminishes after the first weeks of treatment. Joint and muscle discomfort is dose-related and generally resolves with dose adjustment. Patients with pre-existing joint conditions should disclose this to their prescribing clinician, as tesamorelin's musculoskeletal side effect profile may require monitoring adjustment.

Active Malignancy — Absolute Contraindication

Active malignancy is a formal contraindication in the FDA label — not merely a precaution. GH and IGF-1 are mitogenic growth factors. Tesamorelin's clinical program excluded patients with active malignancy. Any use in patients with current or recent cancer requires oncology consultation and is contraindicated per the approved label. This is the primary safety red line for any GHS compound.

Special Populations

Pregnancy: contraindicated; tesamorelin has not been studied in pregnant women and may cause fetal harm. Nursing: use with caution; it is unknown whether tesamorelin is excreted in human milk. Pediatric use: tesamorelin is not indicated for pediatric patients. Renal impairment: no dose adjustment is required. Hepatic impairment: data are limited; use with clinical caution. Elderly patients: age-related changes in GH/IGF-1 axis sensitivity may alter response; monitoring is particularly important.

Regulatory status — 2026

FDA-approved for HIV lipodystrophy. Off-label use is a distinct clinical and regulatory context.

FDA Approval — NDA 022505, November 2010

Tesamorelin (Egrifta, Theratechnologies Inc.) received FDA approval on November 10, 2010 under NDA 022505 for: treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. This is the only FDA approval for any growth hormone secretagogue compound in an adult body composition indication.

The approval is indication-specific. All uses of tesamorelin outside of HIV-associated lipodystrophy — including use in non-HIV adults for body composition optimization, healthy aging protocols, or visceral fat reduction in metabolic syndrome — constitute off-label use. Off-label prescribing by licensed physicians is legal and common, but it is not supported by the Phase 3 regulatory dataset, which was conducted exclusively in HIV+ patients with lipodystrophy. Prescribers must document clinical rationale for off-label use and patients must be informed of the off-label status of any such protocol.

Off-Label Use — Legal, Evidence-Extrapolated

Off-label use of tesamorelin is legally permissible for licensed prescribers who determine it appropriate for a specific patient's clinical situation. The prescriber bears the responsibility of documenting clinical rationale and ensuring the patient understands the off-label nature of the treatment. Evidence supporting off-label use is extrapolated from the HIV lipodystrophy trial data and does not have the same direct clinical validation for non-HIV populations. Discuss with your clinician whether off-label tesamorelin use is appropriate for your specific health situation.

WADA Status — Prohibited Regardless of FDA Approval

Tesamorelin is prohibited in competitive sports under the WADA Prohibited List as a peptide hormone and related substance. FDA approval does not exempt tesamorelin from WADA prohibition. Even in HIV+ patients using tesamorelin under its FDA-approved indication, participation in sanctioned sports would require WADA therapeutic use exemption (TUE) evaluation. Athletes in any sanctioned sport must not use tesamorelin without a verified TUE.

How YourHealthRx approaches it

Evidence-grounded clinical evaluation — with clear communication of approval status.

Tesamorelin in Clinical Context — What Your Consultation Covers

YourHealthRx connects patients with licensed clinical partners nationwide — serving patients across all 50 states and DC through HIPAA-compliant telehealth. For tesamorelin, partner clinicians begin with a full clinical intake that explicitly addresses: whether the patient has an HIV-associated lipodystrophy diagnosis (the approved indication); the rationale and evidence basis if off-label use is being considered; cancer history and malignancy risk screening (a formal contraindication); hypothalamic-pituitary axis integrity; and baseline metabolic labs including IGF-1, fasting glucose, HbA1c, and lipid panel.

Our clinical partners communicate clearly about the distinction between tesamorelin's FDA-approved indication and off-label use when applicable. Tesamorelin has Level I evidence for its approved indication — this is the strongest evidence basis in the GHS class, and this is presented accurately to patients. All off-label prescribing decisions are made by licensed clinicians who document clinical rationale and obtain informed consent. Ongoing IGF-1 monitoring and clinical follow-up are integrated into every protocol.

FAQ

Common questions about tesamorelin.

Is tesamorelin the only FDA-approved GH secretagogue?

Yes. Tesamorelin (Egrifta, Theratechnologies) is the only GH secretagogue compound with FDA approval — approved November 2010 for HIV-associated lipodystrophy (NDA 022505). No other compound in this class has received FDA approval for any adult body composition or GH-related indication. This is the defining clinical distinction of tesamorelin within the GHS class.

What does the Phase 3 trial data actually show?

In the pivotal Phase 3 pooled analysis (Falutz et al., 2010, PMID 20554713), tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by a mean of 24 cm² versus a gain of 2 cm² with placebo (−15.4% treatment effect, p<0.001) at 26 weeks, with sustained reduction at 52 weeks. The 2026 meta-analysis (Badran et al.) confirmed a pooled VAT reduction of −27.71 cm² and lean body mass increase of +1.42 kg across 5 RCTs. This is Level I evidence — the strongest available in any GHS compound.

Can tesamorelin be used if I don't have HIV?

Off-label prescribing of tesamorelin in non-HIV patients is legal for licensed physicians who document clinical rationale. However, FDA approval applies only to HIV-associated lipodystrophy. Evidence supporting non-HIV use is extrapolated from the HIV lipodystrophy trials — it is not independently validated in non-HIV populations. Your clinician will assess whether off-label tesamorelin use is appropriate for your specific situation.

What are the formal contraindications?

Per the FDA-approved label: hypothalamic-pituitary axis disruption (from pituitary tumors, hypophysectomy, head irradiation, or TBI); active malignancy; pregnancy; and hypersensitivity to tesamorelin or excipients. These are hard contraindications applicable to all use — approved or off-label. Clinician screening for these conditions before prescribing is mandatory.

How does tesamorelin affect blood glucose?

The Phase 3 clinical program found glucose parameters were not clinically meaningfully affected — a favorable finding in a population already at metabolic risk from HIV and antiretroviral therapy. This does not mean glucose monitoring is unnecessary; it suggests tesamorelin's pulsatile GH stimulation mechanism may be more metabolically favorable than continuous GH elevation. Fasting glucose and HbA1c monitoring is appropriate in any GHS protocol.

Is tesamorelin the same as Egrifta SV?

Egrifta SV (introduced by Theratechnologies in 2019) is an updated, single-vial liquid formulation of the same active compound — tesamorelin — with a more convenient preparation method compared to the original lyophilized two-vial kit. Both are tesamorelin; the SV formulation offers improved convenience without pharmacological difference from the original approval.

Is tesamorelin prohibited in sports?

Yes — tesamorelin is prohibited under the WADA Prohibited List as a peptide hormone and related substance. FDA approval does not exempt it from WADA prohibition. Athletes in sanctioned sports require a Therapeutic Use Exemption (TUE) if using tesamorelin for the approved medical indication. Athletes without an approved TUE must not use tesamorelin in competition.

How does tesamorelin compare to CJC-1295/Ipamorelin?

Tesamorelin has Level I Phase 3 RCT evidence, FDA approval, and formal safety data in 800+ patients. CJC-1295 has Level II Phase 2 pharmacology data in healthy volunteers; ipamorelin has foundational preclinical pharmacology. The combination protocol is more widely used in clinical telehealth due to accessibility, but tesamorelin has categorically stronger evidentiary support for its body composition effects in the studied population.

Informational only. Content on this page is for informational purposes and does not constitute medical advice. Tesamorelin (Egrifta) is FDA-approved specifically for treatment of excess abdominal fat in HIV-infected patients with lipodystrophy (NDA 022505, November 2010). Use for any other indication constitutes off-label prescribing. All prescriptions are issued at the sole discretion of the prescribing clinician. Not all compounds are available in all states. Last reviewed: May 2026.

Sources

References cited on this page.

Primary References

  • Falutz et al. (2010). Metabolic effects of a growth hormone-releasing factor in patients with HIV. J Clin Endocrinol Metab. PMID: 20554713
  • Badran et al. (2026). Tesamorelin for HIV-related lipodystrophy: meta-analysis. Obes Res Clin Pract. DOI: 10.1016/j.orcp.2026.01.002
  • Sinha et al. (2020). GH secretagogues in adults. Transl Androl Urol. DOI: 10.21037/tau.2019.11.30
  • FDA NDA 022505 — Egrifta (tesamorelin for injection), Theratechnologies Inc., approved November 10, 2010. FDA AccessData
  • Theratechnologies — Egrifta SV (tesamorelin) Prescribing Information, 2019 update. theratech.com

Related

Continue exploring.

CJC-1295 / Ipamorelin

The most widely used GHS combination in clinical telehealth. Not FDA-approved, but mechanistically supported by Phase 2 human pharmacology and the GHRH analog evidence base that tesamorelin's trials help establish as a class.

Read the CJC-1295/Ipamorelin Page

GH Secretagogues — Overview

Return to the hub page for a full comparison of all GHS compounds — mechanism classes, evidence hierarchy, regulatory status, and clinical considerations across the full GHS landscape.

GH Secretagogues Hub

Start a Clinical Evaluation

A licensed clinician can evaluate whether tesamorelin — in its approved indication or off-label — may be appropriate for your clinical situation. Nationwide availability across all 50 states and DC via HIPAA-compliant telehealth.

Start Your Intake

Level I evidence. The only FDA-approved GH secretagogue.

A licensed clinician evaluates your clinical history and determines whether tesamorelin's evidence base applies to your specific situation.

Tesamorelin's Phase 3 RCT data are the strongest available in the GHS class — but the approval is indication-specific. Our partner clinicians communicate this distinction clearly, screen for formal contraindications, and design individualized protocols grounded in the evidence. Nationwide, all 50 states and DC.

Start Your Intake Back to GH Secretagogues